Introduction To evaluate the response rate of primary treatment, its predicting factors, and to analyze survival outcomes in patients with epithelial ovarian/tubal/primary peritoneal carcinoma whom underwent suboptimal surgery.

Methods This study included women whom received suboptimal surgery between May 2006 and December 2020. The data of patient’s clinical information, histopathology, tumor stage, surgical methods and outcomes, adjuvant treatment, and primary treatment outcomes were collected. Follow-up data was documented until 31 March 2023. The oncologic outcomes were analyzed.

Results Total of 320 study patients, overall response rate was 58.1%. The median progression free survival (PFS) duration was 13.167 months [6.675–20.583], and the median overall survival (OS) was 32.850 months [15.008–53.642]. The factors significantly associated with response were received neoadjuvant chemotherapy (NAC) with adjusted odd ratio (aOR) 3.342 (95% CI 1.619–6.900, P=0.001), and high-grade serous carcinoma (HGSC) (aOR 0.153, 95% CI 0.092–0.255, P<0.001). HGSC associated with longer median PFS (15.9 months vs 7.2 months, P<0.001) and median OS (35.221 months vs 11.994 months, P<0.001) compared to non-HGSC.

Conclusion/Implications The oncologic outcomes of study patients were comparable to the landmark trials. HGSC has higher response rate, longer PFS and OS than non-HGSC.

• Download figure
• Open in new tab
• Download powerpoint

Abstract EP282/#263 Figure 1